New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT04418167
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 39 times
Summary
This early-stage study tests a new drug called JSI-1187, either alone or combined with dabrafenib, in people with advanced solid tumors that have certain genetic changes (MAPK pathway mutations). The main goal is to check safety and tolerability, with a secondary look at whether the tumors shrink. About 71 adults with tumors that have not responded to standard treatments are being enrolled. Because this is a Phase 1 trial, it is too early to know if the drug will work, and the study is currently on hold.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Cancer Center
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Cancer Center
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905, United States
-
University of Arizona Comprehensive Cancer Center
Tucson, Arizona, 85724, United States
-
University of California Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JSI-1187 (an ERK1/2 inhibitor) and dabrafenib (a targeted cancer drug)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific genetic mutations.
What could go wrong
This is a very early Phase 1 trial with only 71 participants, so it is primarily testing safety, not effectiveness. The study is currently suspended, and many early cancer drugs fail to show enough benefit to move forward.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.